October 2011

Progenics Pharmaceuticals, Inc. is trimming its staff by 26% and cutting its infectious disease and virology programs so that it can focus solely on its oncology program.

Analysts are optimistic about Exact Sciences financial losses because they reflect the heavy investment in clinical trials for a new noninvasive colorectal cancer test.

When it comes to market capital, Pfizer, Inc. tops a list of major companies in the biosciences market.

The Cleveland Clinic has long been at the forefront of cutting-edge medicine and research. The center's reputation as a world leader in a multitude of fields, including oncology, is undisputed.

A highlight of 3 poster sessions from the 12th International Lung Cancer Congress on August 12, 2011 in Carlsbad, CA.

In the United States, the incidence of lung cancer has increased in those aged >74 years and will likely continue to rise.

Erythropoietin-stimulating agents (ESAs), once considered miracle drugs that enjoyed widespread use for cancer-related anemia, fell into disfavor in 2007.

The availability of effective novel agents for the treatment of multiple myeloma - including thalidomide, lenalidomide, and bortezomib - has validated the concept of maintenance therapy in myeloma patients.

Outcomes in the treatment of acute lymphoblastic leukemia (ALL) differ in children and adults, with pediatric patients (including adolescents and young adults) having much higher cure rates than adults.

Investigators have documented gross under-use of established recommendations for the management of high-grade noninvasive bladder cancer.

William I. Bensinger, MD, tackles the complex subject of the role of hematopoietic stem cell transplantation (HSCT), including when to transplant and whether to use allogeneic versus autologous transplant.

Current treatments revolutionized multiple myeloma but combinations and novel approaches in development promise to make even greater strides in treating this disease.

A conversation with Denise R. Aberle, MD, on the National Lung Screening Trial (NLST) at the 12th International Lung Cancer Congress.

The use of nonaspirin nonsteroidal antiinflammatory drugs (NSAIDs) is associated with an increased risk of renal cell carcinoma (RCC).

Investigators are recommending that black women follow a 'prudent dietary pattern' in lieu of a more Western-style diet to prevent the development of colorectal adenomas.

Johnson & Johnson is warning doctors that the demand for the chemotherapy drug Doxil will likely not be met for months to come.

New data suggest that patients with glioblastoma who are treated with valproic acid, an antiepileptic drug (AED), are likely to outlive patients who receive another type of AED or no AED at all.

New results suggest that a high intake of both natural and synthetic folate is associated with a decreased likelihood of colorectal cancer.

Older patients with breast cancer who have a history of heart disease and/or diabetes have an increased risk of cardiotoxicity during treatment with trastuzumab.

Primary care physicians in the US adhere poorly to established guidelines for genetic counseling and testing for women who are at high risk of breast and ovarian cancer.

As millions of Americans grapple with changes in Medicare and other health insurance coverage, thousands of oncologists could find their medical practices threatened by insolvency.

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Meeting.

With the Statue of Liberty as a symbolic backdrop, nearly 2200 cancer patients, caregivers, and healthcare professionals recently gathered at the 3rd Annual 'Celebrating Life and Liberty' survivorship event.

Here are a few incontrovertible facts: our population is growing and aging; people are living longer; and care is more complex and applied for longer periods, so it is more costly.